Search results
Showing 241 to 255 of 1688 results for carers
In development [GID-TA11316] Expected publication date: TBC
Cladribine for treating relapsing multiple sclerosis [ID6263]
In development [GID-TA11293] Expected publication date: 05 February 2025
Supporting family members, carers and staff:- What types of services or approaches are effective in supporting family members,...
This quality standard covers diagnosing and managing inflammatory bowel disease (Crohn’s disease and ulcerative colitis) in adults, young people and children. It describes high-quality care in priority areas for improvement.
This guideline covers managing ulcerative colitis in children, young people and adults. It aims to help professionals to provide consistent high-quality care and it highlights the importance of advice and support for people with ulcerative colitis.
This guideline covers targeted interventions to prevent misuse of drugs, including illegal drugs, ‘legal highs’ and prescription-only medicines. It aims to prevent or delay harmful use of drugs in children, young people and adults who are most likely to start using drugs or who are already experimenting or using drugs occasionally.
This guideline covers how to make shared decision making part of everyday care in all healthcare settings. It promotes ways for healthcare professionals and people using services to work together to make decisions about treatment and care. It includes recommendations on training, communicating risks, benefits and consequences, using decision aids, and how to embed shared decision making in organisational culture and practices.
Sodium zirconium cyclosilicate for treating hyperkalaemia (partial review of TA599) [ID6439]
In development [GID-TA11561] Expected publication date: 13 August 2025
Dupilumab for treating severe chronic rhinosinusitis with nasal polyposis (Review of TA648) [ID6480]
In development [GID-TA11630] Expected publication date: 11 September 2025
This guideline covers diagnosing and managing drug allergy in all age groups. It aims to make it easier for professionals to tell when someone is having an allergic reaction, by specifying the key signs and patterns to look out for. It also makes recommendations on improving people’s understanding of their drug allergies, and ensuring these are recorded properly in their medical records.
This quality standard covers diagnosing, monitoring and managing asthma in children, young people and adults. It describes high-quality care in priority areas for improvement.
View quality statements for QS25Show all sections
Sections for QS25
- Quality statements
- Quality statement 1 (developmental): Objective tests to support diagnosis
- Quality statement 2: Written personalised action plan
- Quality statement 3: Monitoring asthma control
- Quality statement 4: Follow-up by general practice after emergency care
- Quality statement 5 (developmental): Suspected severe asthma
- Update information
- About this quality standard
This quality standard covers diagnosing and managing cystic fibrosis in infants, children, young people and adults. It describes high-quality care in priority areas for improvement.
This quality standard covers preventing and identifying alcohol problems in the community. It includes policy and practice approaches to prevent harmful alcohol use in adults, young people and children. It is particularly relevant to local authorities, the police, and schools and colleges. It describes high-quality care in priority areas for improvement.
View quality statements for QS83Show all sections
Sections for QS83
Evidence-based recommendations on adalimumab (Humira), etanercept (Enbrel) and ustekinumab (Stelara) for plaque psoriasis in children and young people.
Avelumab with axitinib for untreated advanced renal cell carcinoma (MA review of TA645) [ID6294]
In development [GID-TA11587] Expected publication date: 25 June 2025